A Clinical-Scale Microfluidic Respiratory Assist Device with 3D Branching Vascular Networks.

Autor: Isenberg BC; Bioengineering Division, Draper, Cambridge, MA, 02139, USA., Vedula EM; Bioengineering Division, Draper, Cambridge, MA, 02139, USA., Santos J; Bioengineering Division, Draper, Cambridge, MA, 02139, USA., Lewis DJ; Bioengineering Division, Draper, Cambridge, MA, 02139, USA., Roberts TR; Autonomous Reanimation and Evacuation (AREVA) Research Program, The Geneva Foundation, San Antonio, TX, 78234, USA., Harea G; Autonomous Reanimation and Evacuation (AREVA) Research Program, The Geneva Foundation, San Antonio, TX, 78234, USA., Sutherland D; Bioengineering Division, Draper, Cambridge, MA, 02139, USA., Landis B; Bioengineering Division, Draper, Cambridge, MA, 02139, USA., Blumenstiel S; Bioengineering Division, Draper, Cambridge, MA, 02139, USA., Urban J; Bioengineering Division, Draper, Cambridge, MA, 02139, USA., Lang D; Bioengineering Division, Draper, Cambridge, MA, 02139, USA., Teece B; Bioengineering Division, Draper, Cambridge, MA, 02139, USA., Lai W; Bioengineering Division, Draper, Cambridge, MA, 02139, USA., Keating R; Bioengineering Division, Draper, Cambridge, MA, 02139, USA., Chiang D; Bioengineering Division, Draper, Cambridge, MA, 02139, USA., Batchinsky AI; Autonomous Reanimation and Evacuation (AREVA) Research Program, The Geneva Foundation, San Antonio, TX, 78234, USA., Borenstein JT; Bioengineering Division, Draper, Cambridge, MA, 02139, USA.
Jazyk: angličtina
Zdroj: Advanced science (Weinheim, Baden-Wurttemberg, Germany) [Adv Sci (Weinh)] 2023 Jun; Vol. 10 (18), pp. e2207455. Date of Electronic Publication: 2023 Apr 24.
DOI: 10.1002/advs.202207455
Abstrakt: Recent global events such as COVID-19 pandemic amid rising rates of chronic lung diseases highlight the need for safer, simpler, and more available treatments for respiratory failure, with increasing interest in extracorporeal membrane oxygenation (ECMO). A key factor limiting use of this technology is the complexity of the blood circuit, resulting in clotting and bleeding and necessitating treatment in specialized care centers. Microfluidic oxygenators represent a promising potential solution, but have not reached the scale or performance required for comparison with conventional hollow fiber membrane oxygenators (HFMOs). Here the development and demonstration of the first microfluidic respiratory assist device at a clinical scale is reported, demonstrating efficient oxygen transfer at blood flow rates of 750 mL min⁻ 1 , the highest ever reported for a microfluidic device. The central innovation of this technology is a fully 3D branching network of blood channels mimicking key features of the physiological microcirculation by avoiding anomalous blood flows that lead to thrombus formation and blood damage in conventional oxygenators. Low, stable blood pressure drop, low hemolysis, and consistent oxygen transfer, in 24-hour pilot large animal experiments are demonstrated - a key step toward translation of this technology to the clinic for treatment of a range of lung diseases.
(© 2023 The Authors. Advanced Science published by Wiley-VCH GmbH.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje